Accession codes
References
Cantley LC . The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655–1657.
Kang S, Bader AG, Vogt PK . Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005; 102: 802–807.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
Rudelius M, Pittaluga S, Nishizuka S, Pham T, Fend F, Jaffe ES et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108: 1668–1676.
Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178–4186.
Saal LH, Holm K, Maurer M, Su T, Wang X, Yu JS et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554–2559.
Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64: 5048–5050.
Acknowledgements
We thank Azadali Moorji and Valerie Atizado for their technical services.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abubaker, J., Bavi, P., Al-Harbi, S. et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21, 2368–2370 (2007). https://doi.org/10.1038/sj.leu.2404873
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404873
- Springer Nature Limited
This article is cited by
-
Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling
Laboratory Investigation (2022)
-
Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers
Nature Communications (2022)
-
Advances in targeted therapy for malignant lymphoma
Signal Transduction and Targeted Therapy (2020)
-
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma
Cancer Chemotherapy and Pharmacology (2016)
-
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Journal of Cancer Research and Clinical Oncology (2015)